When was Arteaus Therapeutics founded?

Arteaus Therapeutics was founded in 2011.

Where is Arteaus Therapeutics headquartered?

Arteaus Therapeutics is headquartered in Cambridge, Massachusetts, United States.

What industry is Arteaus Therapeutics in?

Arteaus Therapeutics operates in Biotech, neurology, pharmaceuticals.

How many employees does Arteaus Therapeutics have?

Arteaus Therapeutics has 1-10 employees.

Arteaus Therapeutics

Acquired

Novel CGRP antibody therapy for migraine prevention

Cambridge, United States · Founded 2011

Biotech

neurology

pharmaceuticals

Headquarters: Cambridge, Massachusetts
Employees: 1–10

Founded: 2011
Business Model: B2B

About

Arteaus Therapeutics was a Cambridge, Massachusetts-based virtual biotechnology company focused on developing a novel antibody therapy targeting calcitonin gene-related peptide (CGRP) for the prevention of migraine headaches. Founded in 2011 with an $18 million Series A from Atlas Venture and OrbiMed Advisors, the company licensed the CGRP antibody from Eli Lilly and advanced it through Phase 2 clinical trials before Lilly reacquired full development rights in 2014. Arteaus retained a global royalty interest in the resulting drug, Emgality, which it subsequently sold to Royalty Pharma for $260 million in 2019.

Summary

Arteaus Therapeutics is a Biotech company based in Cambridge, United States, founded in 2011.